NCT06660862View on ClinicalTrials.gov

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide

How darolutamide and hormone therapy affects the step count of older men who have prostate cancer

DRUG

Physician choice Androgen Deprivation (Hormone) Therapy

How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue

Trial Locations (1)

60637

o University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER